AnaptysBio, Inc. (ANAB) Given New $82.00 Price Target at JMP Securities

AnaptysBio, Inc. (NASDAQ:ANAB) had its target price hoisted by JMP Securities from $45.00 to $82.00 in a research report released on Tuesday morning. They currently have an outperform rating on the biotechnology company’s stock.

A number of other equities analysts have also recently issued reports on the company. Credit Suisse Group raised their target price on AnaptysBio from $34.00 to $38.00 and gave the stock an outperform rating in a report on Friday, August 25th. Zacks Investment Research upgraded AnaptysBio from a sell rating to a hold rating in a report on Monday, July 17th. Robert W. Baird initiated coverage on AnaptysBio in a research report on Monday, July 10th. They set an outperform rating and a $36.00 price target on the stock. Royal Bank Of Canada initiated coverage on AnaptysBio in a research report on Thursday, September 14th. They set an outperform rating and a $40.00 price target on the stock. Finally, Stifel Nicolaus reaffirmed a buy rating and set a $35.00 price target on shares of AnaptysBio in a research report on Tuesday, September 12th. Seven investment analysts have rated the stock with a buy rating, AnaptysBio has an average rating of Buy and a consensus price target of $54.43.

Shares of AnaptysBio (NASDAQ ANAB) opened at 70.41 on Tuesday. The firm’s market cap is $1.43 billion. AnaptysBio has a 12-month low of $15.17 and a 12-month high of $70.48. The firm’s 50-day moving average price is $35.88 and its 200 day moving average price is $35.88.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.29. The company had revenue of $7.00 million for the quarter, compared to the consensus estimate of $3.45 million. On average, equities analysts expect that AnaptysBio will post ($1.98) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://ledgergazette.com/2017/10/11/anaptysbio-inc-anab-given-new-82-00-price-target-at-jmp-securities.html.

In related news, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of AnaptysBio stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $24.35, for a total value of $901,924.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Holdings A/S Novo sold 356,300 shares of AnaptysBio stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $21.10, for a total value of $7,517,930.00. Following the completion of the sale, the insider now directly owns 1,936,604 shares in the company, valued at approximately $40,862,344.40. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,133,940 shares of company stock worth $24,223,316.

Institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE acquired a new stake in AnaptysBio in the 1st quarter valued at approximately $123,000. DAFNA Capital Management LLC raised its position in AnaptysBio by 22.2% in the 2nd quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 1,000 shares during the last quarter. New York State Common Retirement Fund acquired a new stake in AnaptysBio in the 2nd quarter valued at approximately $168,000. TIAA CREF Investment Management LLC acquired a new stake in AnaptysBio in the 1st quarter valued at approximately $227,000. Finally, Teachers Advisors LLC raised its position in AnaptysBio by 23.4% in the 2nd quarter. Teachers Advisors LLC now owns 9,520 shares of th

A number of other equities analysts have also recently issued reports on the company. Credit Suisse Group raised their target price on AnaptysBio from $34.00 to $38.00 and gave the stock an outperform rating in a report on Friday, August 25th. Zacks Investment Research upgraded AnaptysBio from a sell rating to a hold rating in a report on Monday, July 17th. Robert W. Baird initiated coverage on AnaptysBio in a research report on Monday, July 10th. They set an outperform rating and a $36.00 price target on the stock. Royal Bank Of Canada initiated coverage on AnaptysBio in a research report on Thursday, September 14th. They set an outperform rating and a $40.00 price target on the stock. Finally, Stifel Nicolaus reaffirmed a buy rating and set a $35.00 price target on shares of AnaptysBio in a research report on Tuesday, September 12th. Seven investment analysts have rated the stock with a buy rating, AnaptysBio has an average rating of Buy and a consensus price target of $54.43.

Shares of AnaptysBio (NASDAQ ANAB) opened at 70.41 on Tuesday. The firm’s market cap is $1.43 billion. AnaptysBio has a 12-month low of $15.17 and a 12-month high of $70.48. The firm’s 50-day moving average price is $35.88 and its 200 day moving average price is $35.88.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.29. The company had revenue of $7.00 million for the quarter, compared to the consensus estimate of $3.45 million. On average, equities analysts expect that AnaptysBio will post ($1.98) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://ledgergazette.com/2017/10/11/anaptysbio-inc-anab-given-new-82-00-price-target-at-jmp-securities.html.

In related news, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of AnaptysBio stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $24.35, for a total value of $901,924.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Holdings A/S Novo sold 356,300 shares of AnaptysBio stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $21.10, for a total value of $7,517,930.00. Following the completion of the sale, the insider now directly owns 1,936,604 shares in the company, valued at approximately $40,862,344.40. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,133,940 shares of company stock worth $24,223,316.

Institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE acquired a new stake in AnaptysBio in the 1st quarter valued at approximately $123,000. DAFNA Capital Management LLC raised its position in AnaptysBio by 22.2% in the 2nd quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 1,000 shares during the last quarter. New York State Common Retirement Fund acquired a new stake in AnaptysBio in the 2nd quarter valued at approximately $168,000. TIAA CREF Investment Management LLC acquired a new stake in AnaptysBio in the 1st quarter valued at approximately $227,000. Finally, Teachers Advisors LLC raised its position in AnaptysBio by 23.4% in the 2nd quarter. Teachers Advisors LLC now owns 9,520 shares of the biotechnology company’s stock valued at $228,000 after buying an additional 1,807 shares during the last quarter. 71.35% of the stock is currently owned by institutional investors and hedge funds.

About AnaptysBio

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply